SK Bioscience Co Ltd Financial Flexibility Index
SK Bioscience Co Ltd financial flexibility index. SK Bioscience Co Ltd (302440) has a Financial Flexibility Index of 0.11x as of September 2025. Free cash flow of ₩91.59 Billion (operating CF ₩20.65 Billion minus capex ₩70.94 Billion) represents 0% of total liabilities (₩847.96 Billion). See SK Bioscience Co Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of SK Bioscience Co Ltd (2018–2024)
Financial flexibility index of SK Bioscience Co Ltd from 2018 to 2024. Historical Financial Flexibility Index trend for SK Bioscience Co Ltd across 7 annual periods. Check SK Bioscience Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
SK Bioscience Co Ltd Financial Flexibility Index by Year (2018–2024)
SK Bioscience Co Ltd financial flexibility index by year from 2018 to 2024. Year-by-year free cash flow to debt coverage for SK Bioscience Co Ltd. For the full cash flow conversion analysis, see cash efficiency ratio of SK Bioscience Co Ltd.
| Year | Flexibility Index | Free Cash Flow (KRW) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.05x | ₩44.20 Billion | ₩-128.02 Billion | ₩821.14 Billion | ▼ -90.0% |
| 2023 | 0.54x | ₩79.64 Billion | ₩29.35 Billion | ₩148.58 Billion | ▲ +542.6% |
| 2022 | -0.12x | ₩-48.47 Billion | ₩-124.96 Billion | ₩400.23 Billion | ▼ -110.6% |
| 2021 | 1.14x | ₩579.50 Billion | ₩536.59 Billion | ₩508.81 Billion | ▲ +161.2% |
| 2020 | 0.44x | ₩130.15 Billion | ₩120.22 Billion | ₩298.44 Billion | ▲ +63.1% |
| 2019 | 0.27x | ₩45.79 Billion | ₩21.82 Billion | ₩171.25 Billion | ▲ +142.0% |
| 2018 | 0.11x | ₩21.21 Billion | ₩14.90 Billion | ₩191.98 Billion | — |